Janux Therapeutics, Inc.
General ticker "JANX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.9B (TTM average)
Janux Therapeutics, Inc. follows the US Stock Market performance with the rate: 0.1%.
Estimated limits based on current volatility of 3.0%: low 16.05$, high 18.10$
Factors to consider:
- Total employees count: 81 (+26.6%) as of 2024
- Top business risk factors: Limited operating history, Profitability concerns, Regulatory and compliance, Economic downturns and volatility, Labor/talent shortage/retention
- Current price 37.5% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [26.23$, 64.90$]
- 2025-12-31 to 2026-12-31 estimated range: [17.07$, 45.49$]
Financial Metrics affecting the JANX estimates:
- Negative: with PPE of -43.1 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1.48 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: negative Industry operating income (median)
Short-term JANX quotes
Long-term JANX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $8.61MM | $8.08MM | $10.59MM |
| Operating Expenses | $75.70MM | $81.06MM | $109.44MM |
| Operating Income | $-67.09MM | $-72.98MM | $-98.85MM |
| Non-Operating Income | $4.03MM | $14.69MM | $29.85MM |
| R&D Expense | $53.44MM | $54.92MM | $68.39MM |
| Income(Loss) | $-63.06MM | $-58.29MM | $-68.99MM |
| Profit(Loss)* | $-63.06MM | $-58.29MM | $-68.99MM |
| Stockholders Equity | $320.74MM | $344.35MM | $1,022.78MM |
| Inventory | $0.70MM | $0.00MM | $0.00MM |
| Assets | $364.01MM | $380.41MM | $1,061.52MM |
| Operating Cash Flow | $-42.92MM | $-50.58MM | $-43.81MM |
| Capital expenditure | $6.45MM | $1.85MM | $0.36MM |
| Investing Cash Flow | $58.27MM | $-41.19MM | $-258.02MM |
| Financing Cash Flow | $0.50MM | $59.55MM | $713.24MM |
| Earnings Per Share** | $-1.52 | $-1.32 | $-1.28 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.